{"nctId":"NCT02980042","briefTitle":"Safety of Switching From Rituximab to Ocrelizumab in MS Patients","startDateStruct":{"date":"2017-01-01","type":"ACTUAL"},"conditions":["Multiple Sclerosis"],"count":200,"armGroups":[{"label":"Switching Group","type":"EXPERIMENTAL","interventionNames":["Drug: Ocrelizumab"]},{"label":"Comparator Group","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Rituximab"]}],"interventions":[{"name":"Ocrelizumab","otherNames":["Ocrevus"]},{"name":"Rituximab","otherNames":["Rituxan"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSwitching group:\n\n* Current active patient of RMMSC\n* 18-65 years\n* Diagnosis of relapsing forms of MS\n* Completed ≥ two doses of rituximab with the last dose having been administered:\n\n  1. Within 12 months of screening and\n  2. At least 6 months prior to the first planned infusion of study drug\n* Are receiving their current infusions of rituximab at the University of Colorado Outpatient Infusion Center\n* Have discussed the possibility of switching to ocrelizumab with their MS provider\n* Screened for Hepatitis B and C and TB within 2 years of first dose of ocrelizumab\n* A negative serum pregnancy test must be available for premenopausal women and for women \\<12 months after the onset of menopause, unless they have undergone surgical sterilization.\n* Women of childbearing potential must agree to use a \"highly effective\", hormonal form of contraception or two \"effective\" forms of non-hormonal contraception. Contraception must continue for the duration of study treatment and for at least three months after the last dose of study treatment\n* Are able to complete patient reported outcomes developed as English written scales.\n* Must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with local regulatory requirements\n\nComparator group:\n\n* Current active patient of RMMSC\n* 18-65 years\n* Diagnosis of relapsing forms of MS\n* Completed ≥ two doses of rituximab with the last dose having been administered within 12 months of screening as standard of care\n* Are receiving their current infusions of rituximab as standard of care at the University of Colorado Outpatient Infusion Center and will continue to do so\n* Are willing to be followed for up to two additional rituximab infusions during the study period as standard of care\n* Must be able and willing to give meaningful, written informed consent prior to participation in the trial, in accordance with local regulatory requirements\n\nExclusion Criteria:\n\nBoth groups:\n\n* Pregnant or lactating women\n* Hypersensitivity to trial medications\n* Hepatic Dysfunction (liver enzymes are 5 times greater than normal)\n* History of Congestive Heart Failure\n* Any history of a positive blood assay for Hepatitis B or C\n* Any history of TB or a positive Quantiferon Gold Assay\n* Concurrent use of immunosuppressant medications\n* Any history of immunodeficiency or other medical condition increasing risk of anti-CD 20 therapy.\n* No serious infection at the time of a scheduled study infusion.\n* Any medical, psychiatric or other condition that could result in the patient not being able to give fully informed consent, or to comply with the protocol requirements as determined by the investigator","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Infusions With >= 1 IRR Between the Switching and Comparator Groups","description":"The investigators will report the proportion of infusions with \\>= 1 IRR (infusion-related reaction) between the switching and comparator groups. Data was collected at Day 1, Day 15, and Week 24 and combined to determine the overall proportion of IRRs over the life of the study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"PRIMARY","title":"Difference in the Total Number of IRRs After Each Infusion of Ocrelizumab Compared to Rituximab Infusions in the Comparator Group.","description":"The investigators will report the difference in the total number of IRRs after each infusion of ocrelizumab compared to combined rituximab infusions in the comparator group.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null}]}]}]},{"type":"PRIMARY","title":"Severity of IRRs Following the Day 1 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions","description":"The severity of IRRs will be assessed following each infusion of ocrelizumab in the switching and comparator group using the National Cancer Institute's Common Terminology for Adverse Events Scale (Grades range from 1-5, with higher Grades indicating more severe reactions). The frequency of each severity grade of IRR will be compared in a similar fashion .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Severity of IRRs Following the Day 15 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions","description":"The severity of IRRs will be assessed following each infusion of ocrelizumab in the switching and comparator group using the National Cancer Institute's Common Terminology for Adverse Events Scale (Grades range from 1-5, with higher Grades indicating more severe reactions). The frequency of each severity grade of IRR will be compared in a similar fashion.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Severity of IRRs Following the Week 24 Infusion of Ocrelizumab in the Switching and the Comparator Groups Infusions","description":"The severity of IRRs will be assessed following each infusion of ocrelizumab in the switching and comparator group using the National Cancer Institute's Common Terminology for Adverse Events Scale (Grades range from 1-5, with higher Grades indicating more severe reactions). The frequency of each severity grade of IRR will be compared in a similar fashion .","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88","spread":null},{"groupId":"OG001","value":"172","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Proportion of Patients With an IRR at Day 1 Versus Day 15 and Week 24 Infusions","description":"We will also compare the proportion of patients with an IRR following day 1 infusion versus the proportion of patients with an IRR at day 15 and month 6 infusions of ocrelizumab in the switching group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"4","spread":null},{"groupId":"OG002","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of Ocrelizumab Anti-drug Anti-bodies","description":"Proportion of ocrelizumab patients who test positive for ocrelizumab anti-drug anti-bodies","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":null},{"groupId":"OG001","value":"1.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Presence of Rituximab Anti-drug Anti-bodies","description":"Proportion of patients who test positive for rituximab anti-drug anti-bodies.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.00","spread":null},{"groupId":"OG001","value":"7.00","spread":null}]}]}]},{"type":"SECONDARY","title":"B Cell Depletion (CD19)","description":"Proportion of patients with CD19% \\<= 1%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.14","spread":null},{"groupId":"OG001","value":"92.00","spread":null},{"groupId":"OG002","value":"90.32","spread":null}]}]}]},{"type":"SECONDARY","title":"B Cell Depletion (CD20)","description":"Proportion of patients with CD20% \\<= 1%","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.70","spread":null},{"groupId":"OG001","value":"92.00","spread":null},{"groupId":"OG002","value":"88.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Cytokine: Eotaxin - Pre-Post Infusion - Day 1","description":"Comparing Eotaxin concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117.44","spread":"50.19"},{"groupId":"OG001","value":"101.41","spread":"55.94"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IFN-gamma - Pre-Post Infusion - Day 1","description":"Comparing IFN-gamma concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"1.42"},{"groupId":"OG001","value":"4.58","spread":"5.28"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-10 - Pre-Post Infusion - Day 1","description":"Comparing IL-10 concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"0.27"},{"groupId":"OG001","value":"8.75","spread":"11.28"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-12/IL-23p40 - Pre-Post Infusion - Day 1","description":"Comparing IL-12/IL-23p40 concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.79","spread":"38.79"},{"groupId":"OG001","value":"52.42","spread":"35.11"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-16 - Pre-Post Infusion - Day 1","description":"Comparing IL-16 concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.48","spread":"40.77"},{"groupId":"OG001","value":"129.80","spread":"80.10"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-1RA - Pre-Post Infusion - Day 1","description":"Comparing IL-1RA concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"196.71","spread":"202.10"},{"groupId":"OG001","value":"550.06","spread":"920.23"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-27 - Pre-Post Infusion - Day 1","description":"Comparing IL-27 concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"643.32","spread":"269.50"},{"groupId":"OG001","value":"820.23","spread":"340.37"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-6 - Pre-Post Infusion - Day 1","description":"Comparing IL-6 concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.29"},{"groupId":"OG001","value":"0.49","spread":"0.56"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-7 - Pre-Post Infusion - Day 1","description":"Comparing IL-7 concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.84","spread":"0.36"},{"groupId":"OG001","value":"1.38","spread":"2.98"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-8(HA) - Pre-Post Infusion - Day 1","description":"Comparing IL-8(HA) concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306.89","spread":"186.64"},{"groupId":"OG001","value":"260.73","spread":"147.40"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MCP-1 - Pre-Post Infusion - Day 1","description":"Comparing MCP-1 concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.83","spread":"14.37"},{"groupId":"OG001","value":"90.09","spread":"146.18"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MDC - Pre-Post Infusion - Day 1","description":"Comparing MDC concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"468.96","spread":"138.66"},{"groupId":"OG001","value":"451.72","spread":"139.53"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MIP-1alpha - Pre-Post Infusion - Day 1","description":"Comparing MIP-1alpha concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.50","spread":"26.72"},{"groupId":"OG001","value":"45.52","spread":"34.45"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MIP-1beta - Pre-Post Infusion - Day 1","description":"Comparing MIP-1beta concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.27","spread":"9.63"},{"groupId":"OG001","value":"453.35","spread":"671.64"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MIP-3alpha - Pre-Post Infusion - Day 1","description":"Comparing MIP-3alpha concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.90","spread":"2.64"},{"groupId":"OG001","value":"5.13","spread":"5.70"}]}]}]},{"type":"SECONDARY","title":"Cytokine: TARC - Pre-Post Infusion - Day 1","description":"Comparing TARC concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.02","spread":"13.54"},{"groupId":"OG001","value":"32.72","spread":"21.79"}]}]}]},{"type":"SECONDARY","title":"Cytokine: TNF-alpha - Pre-Post Infusion - Day 1","description":"Comparing TNF-alpha concentration between pre and post ocrelizumab infusion - Day 1","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.39"},{"groupId":"OG001","value":"2.53","spread":"2.64"}]}]}]},{"type":"SECONDARY","title":"Cytokine: Exotaxin - Pre-Post Infusion - Day 15","description":"Comparing Exotaxin concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"128.38","spread":"54.32"},{"groupId":"OG001","value":"95.79","spread":"60.29"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IFN-gamma - Pre-Post Infusion - Day 15","description":"Comparing IFN-gamma concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"1.37"},{"groupId":"OG001","value":"1.40","spread":"1.49"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-10 - Pre-Post Infusion - Day 15","description":"Comparing IL-10 concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.12","spread":"0.12"},{"groupId":"OG001","value":"2.12","spread":"3.91"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-12/IL-23p40 - Pre-Post Infusion - Day 15","description":"Comparing IL-12/IL-23p40 concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.36","spread":"31.75"},{"groupId":"OG001","value":"41.31","spread":"29.24"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-16 - Pre-Post Infusion - Day 15","description":"Comparing IL-16 concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.35","spread":"54.78"},{"groupId":"OG001","value":"76.62","spread":"29.78"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-1beta - Pre-Post Infusion - Day 15","description":"Comparing IL-1beta concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"0.73"},{"groupId":"OG001","value":"0.95","spread":"0.72"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-7 - Pre-Post Infusion - Day 15","description":"Comparing IL-7 concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.88","spread":"0.64"},{"groupId":"OG001","value":"1.29","spread":"0.95"}]}]}]},{"type":"SECONDARY","title":"Cytokine: IL-8 - Pre-Post Infusion - Day 15","description":"Comparing IL-8 concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.82","spread":"1.48"},{"groupId":"OG001","value":"1.09","spread":"0.80"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MCP-1 - Pre-Post Infusion - Day 15","description":"Comparing MCP-1 concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.57","spread":"18.08"},{"groupId":"OG001","value":"16.33","spread":"9.24"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MCP-4 - Pre-Post Infusion - Day 15","description":"Comparing MCP-4 concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37.38","spread":"23.70"},{"groupId":"OG001","value":"30.38","spread":"15.08"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MDC - Pre-Post Infusion - Day 15","description":"Comparing MDC concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"458.13","spread":"154.72"},{"groupId":"OG001","value":"435.00","spread":"165.94"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MIP-1beta - Pre-Post Infusion - Day 15","description":"Comparing MIP-1beta concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.09","spread":"9.46"},{"groupId":"OG001","value":"17.23","spread":"7.80"}]}]}]},{"type":"SECONDARY","title":"Cytokine: MIP-3alpha - Pre-Post Infusion - Day 15","description":"Comparing MIP-3alpha concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.15","spread":"4.32"},{"groupId":"OG001","value":"3.31","spread":"2.83"}]}]}]},{"type":"SECONDARY","title":"Cytokine: TNF-alpha - Pre-Post Infusion - Day 15","description":"Comparing TNF-alpha concentration between pre and post ocrelizumab infusion - Day 15","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"0.45"},{"groupId":"OG001","value":"0.81","spread":"0.34"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":100},"commonTop":["Upper Respiratory Infection","Headache","Nausea","Numbness"]}}}